ライフサイエンスコーパス: tenecteplase

1 tal of 1820 patients (618 [34%] treated with tenecteplase).

2 ossible harm from treatment with intravenous tenecteplase.

3 ients, 71 received alteplase and 75 received tenecteplase.

4 re assigned to the alteplase group and 52 to tenecteplase.

5 s selective to t-PA and its close derivative tenecteplase.

6 7.1%, p = 0.05) when compared with full-dose tenecteplase.

7 aphic flow patterns, compared with full-dose tenecteplase.

8 therapy with eptifibatide administered with tenecteplase.

9 nogen activator, reteplase, lanoteplase, and tenecteplase.

10 gned to control and 432 (49%) to intravenous tenecteplase.

11 1:1) to either a single intravenous bolus of tenecteplase 0.25 mg per kg of bodyweight (maximum 25 mg

12 ents were randomly assigned (1:1) to receive tenecteplase 0.25 mg/kg (maximum 25 mg) or alteplase 0.9

13 Tenecteplase 0.25 mg/kg was non-inferior to 0.9 mg/kg al

14 o receive intravenous alteplase 0.9 mg/kg or tenecteplase 0.25 mg/kg, by use of a telephone-based int

15 Intra-arterial tenecteplase (0.0625 mg/kg, maximum dose 6.25 mg) admini

16 lase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogra

17 ing patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to

18 The higher dose of tenecteplase (0.25 mg per kilogram) was superior to the

19 with randomly permuted blocks to intravenous tenecteplase (0.25 mg/kg) or alteplase (0.90 mg/kg).

20 sufficient balance algorithm to intravenous tenecteplase (0.25 mg/kg) or non-thrombolytic standard o

21 Intravenous tenecteplase (0.25 mg/kg) vs intravenous alteplase (0.9

22 s thrombolysis with alteplase (0.9 mg/kg) or tenecteplase (0.25 mg/kg).

23 ndomly assigned (1:1) to receive intravenous tenecteplase (0.25 mg/kg, maximum dose of 25 mg) or intr

24 -combination regimen of 50% of standard-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatid

25 kg/min infusion) was compared with full-dose tenecteplase (0.53 microg/kg).

26 owever, in patients with target mismatch (33 tenecteplase, 35 alteplase), treatment with tenecteplase

27 B trial (tissue plasminogen activator versus tenecteplase), 49 centers carried out 2-year follow-up.

28 of recombinant tissue plasminogen activator (tenecteplase, 5 mg/kg) worsened APAP-induced liver injur

29 titutes of Health Stroke Scale score change: tenecteplase, 6; alteplase, 1; P<0.001) and better late

30 titutes of Health Stroke Scale score change: tenecteplase, 7; alteplase, 2; P=0.018) and less parench

31 ere observed with full-dose versus half-dose tenecteplase (75.8% versus 88.9%, P=0.259; 31.0% versus

32 Tenecteplase, a genetically engineered mutant tissue pla

33 st hoc analysis of the Alteplase compared to Tenecteplase (AcT) trial, an investigator-led, registry-

34 tion (TIMI) 10, TIMI 14, and Integrillin and Tenecteplase acute MI trials.

35 or proximal vessel occlusion, intra-arterial tenecteplase administered after successful recanalisatio

36 reperfusion therapy in STEMI (streptokinase, tenecteplase, alteplase, and reteplase) were included.

37 imary PCI or fibrinolytic therapy with bolus tenecteplase (amended to half dose in patients >/=75 yea

38 tery: 104 were randomly allocated to receive tenecteplase and 104 to receive standard care.

39 n 173 (59%) of 295 participants allocated to tenecteplase and 171 (56%) of 306 participants allocated

40 n 191 (57%) of 335 participants allocated to tenecteplase and 188 (55%) of 340 participants allocated

41 roportion of patients with sICH was 1.8% for tenecteplase and 3.6% for alteplase (P < .001), with an

42 Of 71 patients (35 assigned tenecteplase and 36 assigned alteplase) contributing to

43 rtality (19.9% vs 18.1%) were similar in the tenecteplase and alteplase groups, respectively.

44 ological outcomes did not differ between the tenecteplase and alteplase groups.

45 o significant differences were found between tenecteplase and alteplase in effectiveness or safety ou

46 Differences between tenecteplase and alteplase in the risk of sICH were asse

47 Mortality at 90 days was similar between the tenecteplase and control groups: 29 (27.9%) v 28 (26.9%)

48 Combination therapy with reduced-dose tenecteplase and eptifibatide leads to faster, more stab

49 tention-to-treat population (n=885 allocated tenecteplase and n=892 allocated alteplase).

50 t detect any significant differences between tenecteplase and placebo in the primary end point of 30-

51 Tenecteplase and reteplase are comparable with accelerat

52 he development of mutant derivatives such as tenecteplase and reteplase.

53 Six patients assigned to tenecteplase and seven to alteplase did not receive stud

54 c stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no difference bet

55 is (70% received alteplase, and 30% received tenecteplase), and 225 patients (44%) underwent endovasc

56 ctomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo.

57 STEMI and alteplase (accelerated infusion), tenecteplase, and reteplase should be considered over st

58 d between accelerated infusion of alteplase, tenecteplase, and reteplase with parenteral anticoagulan

59 ho received a pharmacoinvasive strategy with tenecteplase (April 2013: half-dose tenecteplase was emp

60 Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after

61 This study supports tenecteplase as a reasonable alternative to alteplase.

62 on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% conf

63 patients aged >=75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, wh

64 reasing interest in replacing alteplase with tenecteplase as the preferred thrombolytic treatment for

65 Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or

66 olytic therapy with alteplase, reteplase, or tenecteplase at full dose should be administered for pat

67 tive or retrospective) comparing intravenous tenecteplase (at any dose) with intravenous alteplase in

68 For major bleeding, a tenecteplase-based regimen tended to be associated with

69 s a prespecified analysis of the Intravenous Tenecteplase Compared With Alteplase for Acute Ischaemic

70 We pooled 2 clinical trials of tenecteplase compared with alteplase for the treatment o

71 milar effectiveness and safety outcomes with tenecteplase compared with alteplase in patients with ac

72 ings in this study indicate that intravenous tenecteplase conferred similar reperfusion, safety, and

73 Information on whether tenecteplase confers benefit beyond 4.5 hours is limited

74 of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral repe

75 findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-

76 ranial hemorrhage occurred after halving the tenecteplase dose.

77 Easier administration of tenecteplase, especially in the context of interhospital

78 r, were randomly assigned (2:1) to half-dose tenecteplase followed by coronary angiography and PCI (i

79 Australia, and the US that used alteplase or tenecteplase for patients treated between July 1, 2018,

80 ts provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clini

81 However, the utility of tenecteplase for the treatment of all AIS patients eligi

82 ther thrombolytic treatment with intravenous tenecteplase given within 4.5 h of awakening improves fu

83 More patients died in the tenecteplase group (20 deaths [5%]) than in the control

84 he control group and 309 (72%) of 432 in the tenecteplase group (risk ratio [RR] 0.96, 95% CI 0.88-1.

85 study product, and five participants in the tenecteplase group and 11 in the alteplase group were lo

86 n 36 h was observed in 15 (2%) of 711 in the tenecteplase group and 13 (2%) of 706 in the alteplase g

87 day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo

88 ation, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and t

89 n treatment groups (28 [10%] patients in the tenecteplase group and 23 [8%] in the control group; adj

90 At 90 days, 36 patients (34.6%) in the tenecteplase group and 27 (26.0%) in the control group h

91 were enrolled (288 randomly assigned to the tenecteplase group and 290 to the control group [intenti

92 population comprised 601 people (295 in the tenecteplase group and 306 in the alteplase group).

93 eeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo

94 d day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group die

95 domization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the pla

96 Nine (3%) of 337 patients in the tenecteplase group and six (2%) of 340 in the alteplase

97 urs occurred in eight patients (8.3%) in the tenecteplase group and three (3.1%) in the control group

98 Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1

99 occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in

100 68 (8%) patients in the tenecteplase group compared with 75 (8%) patients in the

101 days occurred in 46 (7%) individuals in the tenecteplase group versus 35 (5%) in the alteplase group

102 pulation occurred in 439 (62%) of 705 in the tenecteplase group versus 405 (58%) of 696 in the altepl

103 orrhage occurred in six (2%) patients in the tenecteplase group versus three (1%) in the control grou

104 symptomatic intracranial haemorrhages in the tenecteplase group versus two (<1%) in the control group

105 e of penumbral salvaged (68% [SD 28] for the tenecteplase group vs 68% [23] for the alteplase group;

106 s achieved in 86 participants (32.7%) in the tenecteplase group vs 76 (29.6%) in the alteplase group.

107 The tenecteplase group was older (median [IQR], 73 [61-81] y

108 nts did not differ between groups (32 in the tenecteplase group, three considered probably or definit

109 re were more intracranial hemorrhages in the tenecteplase group.

110 Together, the two tenecteplase groups had greater reperfusion (P=0.004) an

111 Patients treated with tenecteplase had better 3-month functional outcomes (com

112 Patients receiving tenecteplase had higher odds of 3-month good functional

113 Intravenous thrombolysis (IVT) with tenecteplase has been associated with better clinical ou

114 The newer thrombolytic drug tenecteplase has been investigated in one randomised tri

115 Tenecteplase has emerged as a potential alternative thro

116 Tenecteplase has potential benefits over alteplase, the

117 Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular

118 Halving the dose of tenecteplase in a pharmaco-invasive strategy in this ear

119 This sub-study of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI)

120 Evaluation of tenecteplase in larger trials of patients with acute str

121 ent evidence does not support treatment with tenecteplase in patients selected with non-contrast CT.

122 bust evidence supporting the introduction of tenecteplase in preference to alteplase.

123 Intravenous tenecteplase increases reperfusion in patients with salv

124 enemia also increased thrombus resistance to tenecteplase-induced thrombolysis in vivo.

125 Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysi

126 First with alteplase and now with tenecteplase, intravenous thrombolysis has remained a co

127 Tenecteplase is an alternative to alteplase for emergenc

128 Evidence from nonrandomized studies suggests tenecteplase is as safe as alteplase and potentially ass

129 Full-dose tenecteplase is associated with an increased risk of int

130 Tenecteplase is being evaluated as an alternative thromb

131 r pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients wit

132 known whether intravenous thrombolysis using tenecteplase is noninferior or preferable compared with

133 Tenecteplase may offer an improved efficacy and safety p

134 Of these patients, 9465 (11.9%) received tenecteplase (mean [SD] age, 69.6 [14.7] years; median N

135 Intravenous thrombolysis with tenecteplase might improve outcomes in this population.

136 improved patient outcomes when treated with tenecteplase (modified Rankin scale score 0-1: odds rati

137 ients were enrolled and randomly assigned to tenecteplase (n=339) and alteplase (n=341), all of whom

138 pants were enrolled and randomly assigned to tenecteplase (n=716) or alteplase (n=714).

139 andomly assigned (1:1) to either intravenous tenecteplase or alteplase and were monitored for up to 1

140 nts with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last kno

141 ed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscita

142 Median times from randomization to tenecteplase or sheath insertion were 10 and 81 minutes,

143 95% CI = 1.31-2.87, p < 0.001), followed by tenecteplase (OR = 1.43, 95% CI = 1.08-1.89, p = 0.01).

144 aimed to test the superiority of intravenous tenecteplase over non-thrombolytic standard of care in p

145 efficacy exists between half- and full-dose tenecteplase pharmaco-invasive treatments with improved

146 Patients were drawn from the low-dose tenecteplase plus eptifibatide arm of the INTEGRITI stud

147 nation reperfusion therapy with reduced-dose tenecteplase plus eptifibatide on continuous ST-segment

148 randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in n

149 he dose-confirmation regimen of reduced-dose tenecteplase plus high-dose eptifibatide was associated

150 ticoagulants (RR 1.47 [95% CI 1.10-1.98] for tenecteplase plus parenteral anticoagulants plus glycopr

151 failed in clinical trials and currently only tenecteplase remains to be tested as a potential alterna

152 t of interhospital transfers, indicates that tenecteplase should be preferred to alteplase for thromb

153 cranial hemorrhage was higher with half-dose tenecteplase than with primary PCI.

154 Tenecteplase therapy that was initiated 4.5 to 24 hours

155 thin 6 h of STEMI enrolled in the Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or W

156 e of either alteplase (tPA) (2 to 5 mg/h) or tenecteplase (TNK) (0.5 mg/h) for a total of 8 h.

157 -TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab.

158 We evaluated whether intravenous tenecteplase (TNK) compared with alteplase (TPA) increas

159 mbinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction

160 ed by the administration of the thrombolytic Tenecteplase (TNK, 1.5 mg/kg, IV bolus) in the presence

161 We aimed to establish the non-inferiority of tenecteplase to alteplase for these patients.

162 then the assertion of the non-inferiority of tenecteplase to alteplase, specifically when perfusion i

163 A total of 331 tenecteplase-treated AIS patients were matched to 797 pa

164 We investigated whether tenecteplase-treated patients had a different 24-hour re

165 Tenecteplase-treated patients had greater early clinical

166 In the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (A

167 We compared the safety and efficacy of tenecteplase versus alteplase in AIS patients by analyzi

168 We aimed to assess the non-inferiority of tenecteplase versus alteplase on clinical outcomes in pa

169 e aimed to assess the efficacy and safety of tenecteplase versus alteplase within 4.5 h of stroke ons

170 her trial results showing non-inferiority of tenecteplase versus alteplase.

171 omized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normotensive patients wit

172 morrhage (by SITS-MOST definition, 1/52 [2%] tenecteplase vs 2/51 [4%] alteplase, p=0.55; by ECASS II

173 Deficits - Intra-Arterial (EXTEND-IA) Trial, Tenecteplase vs Alteplase before Endovascular Thrombecto

174 d clinical experiences with off-label use of tenecteplase vs alteplase for AIS treatment are being pu

175 ational Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERT

176 outcome for non-inferiority (odds ratio for tenecteplase vs alteplase non-inferiority limit of 0.75)

177 % CIs were calculated for the association of tenecteplase vs alteplase with the outcomes of interest

178 to evaluate associations between exposure to tenecteplase (vs alteplase) and end points after adjustm

179 Tenecteplase was administered to 1925 patients.

180 Tenecteplase was administered to 525 patients and placeb

181 arly After Myocardial Infarction), half-dose tenecteplase was an effective and safe pharmaco-invasive

182 IVT with tenecteplase was associated with better 3-month clinical

183 tenecteplase, 35 alteplase), treatment with tenecteplase was associated with greater early clinical

184 y, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than

185 Tenecteplase was associated with significantly better re

186 egy with tenecteplase (April 2013: half-dose tenecteplase was employed in prehospital patients >=75 y

187 The ATTEST-2 trial investigated whether tenecteplase was non-inferior or superior to alteplase w

188 Tenecteplase was non-inferior to alteplase for mRS score

189 Tenecteplase was non-inferior to alteplase in people wit

190 elected with non-contrast CT, treatment with tenecteplase was not associated with better functional o

191 Treatment with tenecteplase was not associated with better functional o

192 When tenecteplase was used without adjunctive antithrombotic

193 Patients receiving IVT with tenecteplase were matched with up to 3 patients receivin

194 tion of the head, and the ability to receive tenecteplase within 4.5 h of awakening.

195 the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase in improving